# Ivanhoe Electric Inc.: financial statements, quarterly

IE · NYSE · CIK 1879016 · [Materials](/sectors/materials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ie.md) · [Financials](/companies/ie/financials.md) · [Filings](/companies/ie/filings.md) · [Insiders](/companies/ie/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ie/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.2](/filings/0001879016-24-000017.md) | [1.7 d](/filings/0001879016-26-000005.md) | [0.4](/filings/0001879016-25-000011.md) | [0.5](/filings/0001879016-25-000016.md) | [0.7](/filings/0001879016-25-000026.md) | [1.3 d](/filings/0001879016-26-000005.md) | [0.7](/filings/0001879016-26-000012.md) | [1.1](/filings/0001879016-26-000017.md) | [0.5](/filings/0001879016-25-000026.md) | [0.9 d](/filings/0001879016-26-000005.md) | [0.9](/filings/0001879016-26-000012.md) | [0.7](/filings/0001879016-26-000017.md) |
| Cost of revenue | $m | [0.3](/filings/0001879016-24-000017.md) | [1.3 d](/filings/0001879016-26-000005.md) | [0.1](/filings/0001879016-25-000011.md) | [0.2](/filings/0001879016-25-000016.md) | [0.3](/filings/0001879016-25-000026.md) | [0.5 d](/filings/0001879016-26-000005.md) | [0.3](/filings/0001879016-26-000012.md) | [0.3](/filings/0001879016-26-000017.md) | [0.3](/filings/0001879016-25-000026.md) | [0.3 d](/filings/0001879016-26-000005.md) | [0.4](/filings/0001879016-26-000012.md) | [0.4](/filings/0001879016-26-000017.md) |
| Gross profit | $m | [(0.0)](/filings/0001879016-24-000017.md) | [0.4 d](/filings/0001879016-26-000005.md) | [0.3](/filings/0001879016-25-000011.md) | [0.3](/filings/0001879016-25-000016.md) | [0.4](/filings/0001879016-25-000026.md) | [0.9 d](/filings/0001879016-26-000005.md) | [0.4](/filings/0001879016-26-000012.md) | [0.8](/filings/0001879016-26-000017.md) | [0.3](/filings/0001879016-25-000026.md) | [0.6 d](/filings/0001879016-26-000005.md) | [0.5](/filings/0001879016-26-000012.md) | [0.4](/filings/0001879016-26-000017.md) |
| Research and development | $m | [1.2](/filings/0001879016-24-000017.md) | [0.9 d](/filings/0001879016-26-000005.md) | [0.8](/filings/0001879016-25-000011.md) | [0.8](/filings/0001879016-25-000016.md) | [0.9](/filings/0001879016-25-000026.md) | [0.3 d](/filings/0001879016-26-000005.md) | [0.1](/filings/0001879016-26-000012.md) | [0.1](/filings/0001879016-26-000017.md) | [0.1](/filings/0001879016-25-000026.md) | [0.1 d](/filings/0001879016-26-000005.md) | [0.4](/filings/0001879016-26-000012.md) | [0.2](/filings/0001879016-26-000017.md) |
| Operating income | $m | [(47.0)](/filings/0001879016-24-000017.md) | [(47.5) d](/filings/0001879016-26-000005.md) | [(56.9)](/filings/0001879016-25-000011.md) | [(48.5)](/filings/0001879016-25-000016.md) | [(41.8)](/filings/0001879016-25-000026.md) | [(29.7) d](/filings/0001879016-26-000005.md) | [(27.0)](/filings/0001879016-26-000012.md) | [(25.6)](/filings/0001879016-26-000017.md) | [(23.6)](/filings/0001879016-25-000026.md) | [(37.3) d](/filings/0001879016-26-000005.md) | [96.8](/filings/0001879016-26-000012.md) | [(21.5)](/filings/0001879016-26-000017.md) |
| Interest expense | $m | [2.6 d](/filings/0001879016-24-000017.md) | [(1.2) d](/filings/0001879016-26-000005.md) | [1.8](/filings/0001879016-25-000011.md) | [1.8 d](/filings/0001879016-25-000016.md) | [1.7 d](/filings/0001879016-25-000026.md) | [(2.4) d](/filings/0001879016-26-000005.md) | [1.7](/filings/0001879016-26-000012.md) | [1.8 d](/filings/0001879016-26-000017.md) | [1.4 d](/filings/0001879016-25-000026.md) | [(2.0) d](/filings/0001879016-26-000005.md) | [1.4](/filings/0001879016-26-000012.md) | [1.4 d](/filings/0001879016-26-000017.md) |
| Income tax | $m | [0.0](/filings/0001879016-24-000017.md) | [(0.4) d](/filings/0001879016-26-000005.md) | [(0.0)](/filings/0001879016-25-000011.md) | [0.0](/filings/0001879016-25-000016.md) | [0.0](/filings/0001879016-25-000026.md) | [0.1 d](/filings/0001879016-26-000005.md) | [0.0](/filings/0001879016-26-000012.md) | [0.0](/filings/0001879016-26-000017.md) | [0.0](/filings/0001879016-25-000026.md) | [0.0 d](/filings/0001879016-26-000005.md) | [12.2](/filings/0001879016-26-000012.md) | [(0.1)](/filings/0001879016-26-000017.md) |
| Net income | $m | [(83.3)](/filings/0001879016-24-000017.md) | [(32.7) d](/filings/0001879016-26-000005.md) | [(60.1)](/filings/0001879016-25-000011.md) | [(46.8)](/filings/0001879016-25-000016.md) | [(43.2)](/filings/0001879016-25-000026.md) | [16.9 d](/filings/0001879016-26-000005.md) | [(30.5)](/filings/0001879016-26-000012.md) | [(23.9)](/filings/0001879016-26-000017.md) | [(17.5)](/filings/0001879016-25-000026.md) | [(34.0) d](/filings/0001879016-26-000005.md) | [41.7](/filings/0001879016-26-000012.md) | [(24.7)](/filings/0001879016-26-000017.md) |
| Diluted EPS | $ per share | [0.74](/filings/0001879016-24-000017.md) | not reported | [0.46](/filings/0001879016-25-000011.md) | [0.39](/filings/0001879016-25-000016.md) | [0.36](/filings/0001879016-25-000026.md) | not reported | [0.24](/filings/0001879016-26-000012.md) | [0.18](/filings/0001879016-26-000017.md) | [0.13](/filings/0001879016-25-000026.md) | not reported | [(0.26)](/filings/0001879016-26-000012.md) | [0.16](/filings/0001879016-26-000017.md) |
| Basic EPS | $ per share | [0.74](/filings/0001879016-24-000017.md) | not reported | [0.46](/filings/0001879016-25-000011.md) | [0.39](/filings/0001879016-25-000016.md) | [0.36](/filings/0001879016-25-000026.md) | not reported | [0.24](/filings/0001879016-26-000012.md) | [0.18](/filings/0001879016-26-000017.md) | [0.13](/filings/0001879016-25-000026.md) | not reported | [(0.27)](/filings/0001879016-26-000012.md) | [0.16](/filings/0001879016-26-000017.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:ProfitLoss, us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [249](/filings/0001879016-24-000017.md) | [205](/filings/0001879016-26-000005.md) | [179](/filings/0001879016-25-000011.md) | [134](/filings/0001879016-25-000016.md) | [81.1](/filings/0001879016-25-000026.md) | [41.0](/filings/0001879016-26-000005.md) | [98.2](/filings/0001879016-26-000012.md) | [88.1](/filings/0001879016-26-000017.md) | [69.5](/filings/0001879016-25-000026.md) | [173](/filings/0001879016-26-000017.md) | [290](/filings/0001879016-26-000012.md) | [257](/filings/0001879016-26-000017.md) |
| Current assets | $m | [261](/filings/0001879016-23-000013.md) | [216](/filings/0001879016-25-000003.md) | [192](/filings/0001879016-24-000009.md) | [147](/filings/0001879016-24-000013.md) | [105](/filings/0001879016-24-000017.md) | [69.3](/filings/0001879016-26-000005.md) | [114](/filings/0001879016-25-000011.md) | [104](/filings/0001879016-25-000016.md) | [87.7](/filings/0001879016-25-000026.md) | [180](/filings/0001879016-26-000017.md) | [301](/filings/0001879016-26-000012.md) | [270](/filings/0001879016-26-000017.md) |
| Total assets | $m | [533](/filings/0001879016-23-000013.md) | [487](/filings/0001879016-25-000003.md) | [461](/filings/0001879016-24-000009.md) | [416](/filings/0001879016-24-000013.md) | [375](/filings/0001879016-24-000017.md) | [375](/filings/0001879016-26-000005.md) | [414](/filings/0001879016-25-000011.md) | [400](/filings/0001879016-25-000016.md) | [386](/filings/0001879016-25-000026.md) | [483](/filings/0001879016-26-000017.md) | [594](/filings/0001879016-26-000012.md) | [585](/filings/0001879016-26-000017.md) |
| Current liabilities | $m | [62.5](/filings/0001879016-23-000013.md) | [39.7](/filings/0001879016-25-000003.md) | [39.2](/filings/0001879016-24-000009.md) | [40.2](/filings/0001879016-24-000013.md) | [41.9](/filings/0001879016-24-000017.md) | [33.4](/filings/0001879016-26-000005.md) | [37.2](/filings/0001879016-25-000011.md) | [27.1](/filings/0001879016-25-000016.md) | [62.0](/filings/0001879016-25-000026.md) | [53.9](/filings/0001879016-26-000017.md) | [48.2](/filings/0001879016-26-000012.md) | [53.5](/filings/0001879016-26-000017.md) |
| Total liabilities | $m | [144](/filings/0001879016-23-000013.md) | [111](/filings/0001879016-25-000003.md) | [111](/filings/0001879016-24-000009.md) | [113](/filings/0001879016-24-000013.md) | [115](/filings/0001879016-24-000017.md) | [94.5](/filings/0001879016-26-000005.md) | [99.0](/filings/0001879016-25-000011.md) | [89.7](/filings/0001879016-25-000016.md) | [92.4](/filings/0001879016-25-000026.md) | [59.7](/filings/0001879016-26-000017.md) | [48.6](/filings/0001879016-26-000012.md) | [54.2](/filings/0001879016-26-000017.md) |
| Shareholders' equity | $m | [388](/filings/0001879016-23-000013.md) | [374](/filings/0001879016-25-000003.md) | [331](/filings/0001879016-24-000009.md) | [289](/filings/0001879016-24-000013.md) | [250](/filings/0001879016-24-000017.md) | [269](/filings/0001879016-26-000005.md) | [307](/filings/0001879016-25-000011.md) | [293](/filings/0001879016-25-000016.md) | [280](/filings/0001879016-25-000026.md) | [416](/filings/0001879016-26-000017.md) | [540](/filings/0001879016-26-000012.md) | [526](/filings/0001879016-26-000017.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(41.1) d](/filings/0001879016-24-000017.md) | [(43.5) d](/filings/0001879016-26-000005.md) | [(50.0)](/filings/0001879016-25-000011.md) | [(44.5) d](/filings/0001879016-25-000016.md) | [(36.9) d](/filings/0001879016-25-000026.md) | [(30.7) d](/filings/0001879016-26-000005.md) | [(25.5)](/filings/0001879016-26-000012.md) | [(20.0) d](/filings/0001879016-26-000017.md) | [(18.0) d](/filings/0001879016-25-000026.md) | [(25.7) d](/filings/0001879016-26-000005.md) | [(42.3)](/filings/0001879016-26-000012.md) | [(20.0) d](/filings/0001879016-26-000017.md) |
| Capital expenditure | $m | [0.6 d](/filings/0001879016-24-000017.md) | [0.4 d](/filings/0001879016-26-000005.md) | [0.7](/filings/0001879016-25-000011.md) | [0.5 d](/filings/0001879016-25-000016.md) | [0.1 d](/filings/0001879016-25-000026.md) | [1.7 d](/filings/0001879016-26-000005.md) | [0.0](/filings/0001879016-26-000012.md) | [1.3 d](/filings/0001879016-26-000017.md) | [(0.1) d](/filings/0001879016-25-000026.md) | [0.0 d](/filings/0001879016-26-000005.md) | [0.6](/filings/0001879016-26-000012.md) | [0.2 d](/filings/0001879016-26-000017.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [92.9](/filings/0001879016-23-000013.md) | [93.0](/filings/0001879016-24-000009.md) | [93.1](/filings/0001879016-24-000013.md) | [105](/filings/0001879016-24-000017.md) | [120](/filings/0001879016-25-000011.md) | [120](/filings/0001879016-25-000016.md) | [120](/filings/0001879016-25-000026.md) | [127](/filings/0001879016-26-000012.md) | [133](/filings/0001879016-26-000017.md) | [133](/filings/0001879016-25-000026.md) | [158](/filings/0001879016-26-000012.md) | [158](/filings/0001879016-26-000017.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 159,590,259 at 2026-08-07, from the cover of the [10-Q filed 2026-08-07](/filings/0001879016-26-000017.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.